CLINICAL PRACTICE

Caren G. Solomon, M.D., M.P.H., Editor

Acute Severe Hypertension

Aldo J. Peixoto, M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A 58-year-old woman with known hypertension comes to the emergency department and reports headaches and blurred vision for the past 3 days. Her prescribed medications include amlodipine, hydrochlorothiazide, and lisinopril, but she acknowledges spotty adherence and has not taken any of the drugs in approximately 3 weeks. On examination, she is anxious but comfortable. The average of multiple seated bloodpressure measurements is 242/134 mm Hg, and the heart rate is 68 beats per minute. Funduscopy shows arteriolar narrowing, bilateral flame hemorrhages, cotton-wool spots, and papilledema; auscultation reveals a fourth heart sound. The remainder of the examination is normal. The electrocardiogram shows left ventricular hypertrophy. Other laboratory tests and chest radiography are normal. Emergency computed tomography of the head shows heterogeneous hypoattenuation of subcortical white matter in the posterior parieto-occipital regions bilaterally but no hemorrhage or infarction. How would you further evaluate and treat this patient?

THE CLINICAL PROBLEM

B LOOD-PRESSURE ELEVATIONS ABOVE 180/110 TO 120 MM HG CAN RESULT in acute injury to the heart, brain, and the microvasculature.¹⁻³ If acute hypertension-mediated target-organ damage is present, the condition is labeled "hypertensive emergency" and demands immediate and aggressive treatment to limit progressive injury (Fig. 1). There is less agreement on terminology and management in the absence of acute target-organ damage (which I will refer to here as "hypertensive urgency"), although this condition is two to three times more common than hypertensive emergency.^{4,5} Acute severe hypertension, at times with acute target-organ damage,⁶ may also manifest perioperatively; the present review focuses on the occurrence of acute severe hypertension outside the perioperative setting. Similarly, the recommendations in this article do not apply to hypertension during pregnancy.

Both absolute blood-pressure level and the pace of rise determine the risk of acute hypertension-mediated target-organ damage. Many patients with chronic hypertension have severe blood-pressure elevations for months or years without apparent effects, whereas sudden increases that are more modest (e.g., to a level of 160/100 mm Hg in a previously normotensive patient) can cause severe injury, particularly to the cerebral vasculature (as in eclampsia, pheochromocytoma, drug-induced acute hypertension, or acute glomerulonephritis).

From the Department of Internal Medicine, Section of Nephrology, Yale School of Medicine, and the Hypertension Program, Yale New Haven Hospital Heart and Vascular Center, New Haven, CT. Address reprint requests to Dr. Peixoto at Boardman 114 (Nephrology), 330 Cedar St., New Haven, CT 06520, or at aldo.peixoto@ yale.edu.

N Engl J Med 2019;381:1843-52. DOI: 10.1056/NEJMcp1901117 Copyright © 2019 Massachusetts Medical Society.



N ENGLJ MED 381;19 NEJM.ORG NOVEMBER 7, 2019

1843

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

KEY CLINICAL POINTS

ACUTE SEVERE HYPERTENSION

- Acute severe hypertension that is accompanied by acute target-organ injury (hypertensive emergency) is associated with substantial morbidity and in-hospital mortality, thus requiring immediate treatment in an intensive care unit.
- Acute severe hypertension without acute target-organ damage (hypertensive urgency) is not associated with adverse short-term outcomes and can be managed in the ambulatory setting.
- Nonadherence to previously prescribed antihypertensive medications is the most common factor leading to acute severe hypertension.
- Chronic hypertension shifts the cerebral blood flow autoregulation curve to the right (i.e., to higher blood-pressure levels), which confers a predisposition to cerebral hypoperfusion at relatively high (normal) blood-pressure levels. This principle guides the pace of blood-pressure reduction in acute severe hypertension.
- Hypertensive emergencies are managed with intravenous medications guided by the type of target-organ damage.
- Hypertensive urgencies should be managed with oral medications and arrangements for prompt follow-up.

Acute severe hypertension accounts for an estimated 4.6% of all visits to emergency departments and is a frequent reason for hospitalizations in the United States.⁵ It is more common in persons who are older than 60 years of age, black, or uninsured or underinsured or who live in lower-income areas.^{5,7} Large claims-based data sets in the United States indicate that hospital admissions for hypertensive emergencies have steadily increased during the past 20 years,^{5,7-9} but in-hospital mortality has improved over time and currently ranges between 0.2% and 11%.⁸⁻¹⁰

Even in the absence of acute target-organ damage, episodes of severe hypertension have long-term implications. In a study involving 2435 patients with a previous transient ischemic attack, an isolated systolic blood pressure above 180 mm Hg (without symptoms) was associated with an increase in stroke risk during 3 years of follow-up by a factor of 5, as compared with no episodes of systolic blood pressure above 140 mm Hg, regardless of usual blood pressures.¹¹ Similarly, a prospective cohort study showed that patients who had an admission with hypertensive urgency had a 50% higher risk of fatal or nonfatal cardiovascular events than controls, despite similar blood-pressure levels during follow-up.¹²

In contrast to these long-term implications, hypertensive urgencies do not appear to be associated with adverse short-term outcomes.¹³⁻¹⁶ Although rates of admission to the hospital are relatively high (up to 11% during the 30 days after initial presentation^{10,15}), studies have not shown increased risks of adverse outcomes in the days to several months after patients were sent home from the office or emergency department.^{13,15,16} A recent analysis of 58,535 ambulatory office encounters with patients who had a systolic blood pressure of 180 mm Hg or higher, a diastolic blood pressure of 110 mm Hg or higher, or both (mean, 182.5/96.4 mm Hg) showed a similar incidence of cardiovascular events at 6 months (0.9%) among patients who were hospitalized and among propensity-matched patients who were discharged after the encounter.¹⁵

STRATEGIES AND EVIDENCE


Figure 1 outlines a structured approach to the management of acute severe hypertension. The key elements include accurate measurement of blood-pressure levels; careful evaluation for potential precipitants, symptoms, and evidence of target-organ damage; and treatment decisions based on the presence of symptoms or acute target-organ damage.

BLOOD-PRESSURE MEASUREMENT

Blood pressure must be measured in both arms and the thigh using appropriate technique and validated devices¹⁷ (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). Most hospitals use automated devices that rely on oscillometric measurements. Two large registry studies comparing oscillometric and intraarterial measurements in critical care¹⁸ or surgical¹⁹ patients showed that oscillometric devices consistently underestimate blood-pressure levels by as much as 50/30 mm Hg when recorded intraarterial levels are above

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.



stable angina and myocardial infarction. With respect to large vessels (aorta), ask about chest or back pain. Obtain blood-pressure measurements in both arms and thigh, looking for asymmetry. If suspicion is aroused, obtain CT of the chest and abdomen with contrast or transesophageal echocardiography. With respect to the kidneys, measure the serum creatinine level to rule out acute kidney injury. Urinalysis may show proteinuria or hematuria as a sign of microvascular injury. With respect to the microvasculature, obtain a complete blood count, looking for anemia and thrombocytopenia suggestive of microangiopathy. ADHF denotes acute decompensated heart failure, IV intravenous, MAHA microangiopathic hemolytic anemia, and PRES posterior reversible encephalopathy syndrome. Adapted from Whelton et al.1

that use aneroid or mercury devices also have cause of the potential underestimation of the substantial discordance from intraarterial measurements in high blood-pressure ranges,^{20,21}

180/100 mm Hg. Auscultatory measurements even when meticulous technique is applied. Beseverity of hypertension, the use of oscillometric (and auscultatory) devices should be discouraged

N ENGL J MED 381;19 NEJM.ORG NOVEMBER 7, 2019

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

when evidence of target-organ damage is present and intravenous agents are required. In such cases, placement of an arterial catheter is indicated. In the absence of target-organ damage, noninvasive oscillometric or auscultatory devices are typically used to guide treatment, despite their limitations.

DETERMINATION OF PRECIPITATING FACTORS

Most patients presenting with acute severe hypertension are already known to be hypertensive and have received treatment.^{15,22} Nonadherence to prescribed antihypertensive medications is the most common precipitating factor. In a large ambulatory database, three quarters of the patients who were evaluated for a systolic blood pressure of 180 mm Hg or higher or a diastolic blood pressure of 110 mm Hg or higher had a diagnosis of hypertension, and more than half had already been prescribed two or more antihypertensive agents.¹⁵ In a prospective study involving patients with hypertension, nonadherence to medication was the strongest predictor of a hypertensive crisis.²³ These data underscore the importance of interventions that improve treatment adherence²⁴ (e.g., the use of patient monitoring of blood pressure, social-support opportunities,²⁵ and partnerships with health coaches, nurses, or pharmacists²⁵⁻²⁷), although studies are lacking to show that these interventions reduce the risk of acute severe hypertension.

Other common precipitating factors for acute severe hypertension include dietary sodium indiscretion; use of prescribed, over-the-counter, or illicit drugs (e.g., cocaine, amphetamines, sympathomimetic agents, nonsteroidal antiinflammatory drugs, and high-dose glucocorticoids); anxiety or panic; and acute stroke or heart failure, which can be both cause and consequence of severe hypertension. Patients with acute glomerulonephritis, preeclampsia, pheochromocytoma, or scleroderma renal crisis may present with acute severe hypertension. Among hospitalized patients, mobilization of infused intravenous fluids, withholding of antihypertensive medications, pain, and urinary retention are considered common precipitants. For patients presenting without a clear precipitant or who meet criteria for treatment-resistant hypertension during follow-up,²⁸ further testing should be considered for secondary causes of hypertension, such as renovascular disease, primary aldosteronism, glucocorticoid excess, pheochromocytoma, and, in younger patients, coarctation of the aorta.

EVALUATION OF ACUTE TARGET-ORGAN DAMAGE

A key part of the initial evaluation is the assessment of symptoms, signs, and diagnostic tests suggestive of acute target-organ damage (Fig. 1), including injury to the brain, heart, large vessels (aorta in particular), kidneys, and the microvasculature (including the retina). Diffuse microvascular injury (also known as "malignant hypertension") manifests as high-grade retinopathy, acute kidney injury, or microangiopathic hemolytic anemia and thrombocytopenia. These features may occur together or in isolation.

In the absence of symptoms to guide the evaluation, there are limited data on the yield of diagnostic tests. In a prospective study involving 167 patients in the emergency department with a triage diastolic blood pressure of 100 mm Hg or higher (mean, 194/112 mm Hg), routine metabolic panels revealed acute kidney injury requiring admission in 7% of patients.²⁹ In retrospective studies, the results of most diagnostic tests that are obtained in patients without evidence of acute target-organ damage have been normal or simply reflective of long-term exposure to hypertension.14,15,30 Still, it is common practice to obtain a basic metabolic panel to assess renal function and electrolyte levels, a complete blood count to screen for microangiopathy, a urinalysis to identify proteinuria or hematuria, and an electrocardiogram and troponin levels to rule out asymptomatic myocardial injury.

Patients without target-organ damage are usually asymptomatic.^{22,31,32} Symptoms, when present, may include headache, atypical chest pain, dyspnea, dizziness, lightheadedness, and epistaxis.

TREATMENT

AUTOREGULATION OF CEREBRAL BLOOD FLOW

Autoregulation of organ blood flow refers to physiological adaptations that allow organ perfusion to remain relatively constant across a wide blood-pressure range (Fig. 2). In the context of acute severe hypertension, flow autoregulation is most important; this autoregulation is best studied in the brain,³³ although the same principles are applicable to most end organs. In chronic severe hypertension, cerebral blood flow is maintained at similar levels as in normal per-

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

sons, but its autoregulatory curve is shifted to the right. This shift allows patients to tolerate higher blood-pressure levels without cerebral edema^{33,34} but confers a predisposition to cerebral hypoperfusion at substantively higher bloodpressure levels than in normotensive persons, although these curves are neither consistent nor predictable at the individual level.^{34,35} Limited data suggest that treatment of severe hypertension for several months may improve autoregulation to a modest extent,³⁴ whereas patients with mild-to-moderate hypertension (<180/110 mm Hg) recover autoregulatory responses within weeks after the initiation of effective therapy.³⁶

CHOICE OF TREATMENT

There are relatively few trials comparing different agents for hypertensive emergency and hypertensive urgency.³⁷⁻³⁹ Treatment is largely determined by an understanding of the pathophysiological features, the presence and type of target-organ injury, the availability and costs of medications, and physician experience with given agents.^{10,40} There is considerable variability in practice regarding the choice of medications.^{10,40}

HYPERTENSIVE EMERGENCIES

All patients should be admitted to an intensive care unit and treated with intravenous antihypertensive drugs on the basis of the clinical scenario (Tables 1 and 2 and Table S2). In the United States, labetalol, nitroglycerin, nicardipine, hydralazine, and nitroprusside are the most commonly used agents.¹⁰ Of these medications, hydralazine has unpredictable effects, often leads to excessive blood-pressure lowering,41 and should generally be avoided as a first option.^{1,3} Studies comparing labetalol and nicardipine have shown faster achievement of blood-pressure control and less variability in blood pressure (allowing blood pressure to stay closer to target) with nicardipine but no significant differences in adverse events or mortality.^{39,42,43} In one trial comparing clevidipine with nicardipine, clevidipine resulted in less variability than nicardipine.38

In the absence of studies comparing different rates of blood-pressure reduction, management is guided by autoregulatory principles; guidelines recommend that blood pressure be decreased by no more than 20 to 25% during the first hour and then to 160/100 to 110 mm Hg during the ensuing 2 to 6 hours.¹ Excessive blood-pressure




Figure 2. Autoregulation of Cerebral Blood Flow and Implications for the Treatment of Hypertensive Emergencies.

Cerebral blood flow is relatively stable across a wide blood-pressure range through changes in cerebrovascular resistance. On the high end of the curve, increased cerebrovascular resistance prevents pressure-induced increases in blood flow. Once the upper limit of autoregulation is crossed, small changes in blood pressure produce substantial increases in blood flow that result in vasogenic cerebral edema and its complications. On the low end of the curve, decreased cerebrovascular resistance allows flow to be maintained despite progressively lower blood pressure. Once the autoregulatory limit is reached, small decreases in blood pressure produce substantial impairment in cerebral perfusion. In clinical experiments, the lower limit of autoregulation occurs at blood-pressure levels approximately 25% lower than baseline. Symptoms of cerebral hypoperfusion develop when cerebral blood flow falls by more than approximately 30%. There is wide individual variability in autoregulatory limits and thresholds at both ends of the curve. The autoregulatory curve is shifted to the right in uncontrolled hypertension. Treatment of hypertension for weeks to months may improve or correct the autoregulatory abnormalities, especially in patients without long-standing severe hypertension.

reduction (resulting in systolic blood pressure below 100 to 120 mm Hg) may occur in up to 10% of patients^{10,40} and is associated with an increased risk of death.44,45 If excessive bloodpressure reduction occurs, prompt discontinuation of intravenous drugs and, in some cases, temporary use of vasopressors, intravenous fluids, or both is indicated. Resumption or initiation of long-acting antihypertensive drugs should take place alongside intravenous therapy to provide a smoother transition, shorten the need for intravenous drugs and intensive care, and minimize the risk of rebound hypertension, which is also associated with increased mortality.44 The appropriate timing for starting or restarting oral drugs is uncertain; because the risk of hypoten-

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

Table 1. Treatment Strategies in Hypertensive Emergencies.*	pertensive Emergencies.*	
Acute Target-Organ Damage	Timing for Acute BP Reduction	Preferred Intravenous Drugs☆
Diffuse microvascular injury ("malignant hypertension")§	Decrease BP by 20–25% during first hr and to 160/100 mm Hg by 2–6 hr	Labetalol, nicardipine, nitroprusside
Hypertensive encephalopathy	Decrease BP by 20–25% during first hr and to 160/100 mm Hg by 2–6 hr	Labetalol, nicardipine, nitroprusside; avoid hydralazine
Acute intracerebral hemorrhage	If systolic BP is 150–220 mm Hg, decrease systolic BP to 140–150 mm Hg within 1 hr, particularly in patients without known hypertension and those with underlying vascular abnormalities, such as aneurysms or arteriovenous malformations. In patients with large hematoma volume and evidence of increased intracranial pressure, BP management should be more liberal (keep systolic BP <180 mm Hg). Lowering systolic BP below 140 mm Hg may be harmful.	Labetalol, nicardipine, clevidipine, nitroprusside; avoid hydral- azine
Acute ischemic stroke	If thrombolytic therapy is indicated, decrease BP to <185/110 mm Hg before giving thrombolytic agents and maintain BP <180/105 mm Hg for the first 24 hr. If thrombolytic therapy is not indicated and there is no acute target-organ damage other than stroke, the strategy depends on BP. If BP is <220/120 mm Hg, no intervention is indicated for the first 48–72 hr. If BP is ≥220/120 mm Hg or there is other acute target-organ damage, such as heart failure or myocardial infarction, decrease BP by 15% within 1 hr.	Labetalol, nicardipine, clevidipine, nitroprusside; avoid hydral- azine
Acute coronary syndromes	Decrease systolic BP to <140 mm Hg within 1 hr; keep diastolic BP >60 mm Hg	Nitroglycerin, labetalol, esmolol, metoprolol; avoid hydralazine
Acute heart failure	Decrease systolic BP to <140 mm Hg within 1 hr	Nitroglycerin, nitroprusside; loop diuretics needed in most cases; enalaprilat or hydralazine may be useful; avoid beta-blockers
Aortic dissection	Decrease both systolic BP to <120 mm Hg and heart rate to <60 beats/min within 20 min	Esmolol (or labetalol) plus one of nicardipine, clevidipine, nitro- prusside, or nitroglycerin; both a beta-blocker (unless brady- cardia is already present) and a vasodilator should be used
 * BP denotes blood pressure. † Initiation, reinstatement, or adjustment tional guidelines. Intravenous medication * Nitroprusside continues to be a recomn * Diffuse microvascular injury is identifie. © Diffuse microvascular injury is identifienenia, present alone or in combination. 	* BP denotes blood pressure. ↑ Initiation, reinstatement, or adjustments of long-acting oral antihypertensive medications should take place during the first 6 to 12 hours. Oral drugs are chosen on the basis of conventional guidelines. Intravenous medications can be tapered on the basis of observed blood-pressure levels after the addition of oral agents. ★ Nitroprusside continues to be a recommended agent by most guidelines. Given its potential toxicity, it should be avoided as a first choice when other options are available. ★ Diffuse microvascular injury is identified as high-grade retinopathy (hemorrhages, exudates, or papilledema), acute kidney injury, or microangiopathic hemolytic anemia or thrombocytopenia, present alone or in combination.	e first 6 to 12 hours. Oral drugs are chosen on the basis of conven- dition of oral agents. ided as a first choice when other options are available. dney injury, or microangiopathic hemolytic anemia or thrombocyto-

N ENGLJ MED 381;19 NEJM.ORG NOVEMBER 7, 2019

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

NicadpineDipologramin of later dilator dilator dilator dilator dilator dilator1.51 mg/m (M dip dilator dilator dilator brannel lobeler, vaso- dilator2.51 mg/m (M dip dilator dilator brannel lobeler, vaso- 2.51 mg/m (M dip dilator2.51 mg/m (M dip dilator to mannel lobeler, vaso- 2.51 mg/m (M dip dilator2.51 mg/m (M dip dilator to mannel lobeler, vaso- 2.51 mg/m (M dip dilator2.61 mg/m (M dip dilator to mannel lobeler, vaso- slow) as 8P appoudets gal slow) as 8P appoudets gal slow) as 8P appoudets gal slow) as 8P appoudets gal action (1.5-15 mil) bu dilator2.16 mg/m (M dip dilator to mannel lobeler, vaso- slow) as 8P appoudets gal action (1.5-15 mil) bu dilator2.16 mg/m (M dip dilator)2.16 mg/m (M dip dilator) <th< th=""><th>Drug</th><th>Class</th><th>Dose</th><th>Onset and Offset of Action</th><th>Cautions</th></th<>	Drug	Class	Dose	Onset and Offset of Action	Cautions
Dilydropyridine calcium. 1-16 mg/hr IV drip: double calcium dotser (5-15 min) of channel blocker, vaso. Channel blocker, vaso. Los my seperat at same dotse after blocker and alpha-1 drip may repeat at same blocker (W bert-to-appox. 71) dotsen (M be	Nicardipine	Dihydropyridine calcium- channel blocker, vaso- dilator	5–15 mg/hr IV drip; adjust by 2.5 mg/hr every 5–15 min	Rapid onset (2–5 min); duration of action, 1–4 hr; adjust dose more slowly (every 15 min) in pa- tients with impaired renal or liver function	Contraindicated in patients with acute coronary ischemia (because of reflex tachycardia)
Combined nonselective blocker (M beat-an alpha: 1 orign may repeat at stame blocker (M beat-an alpha: 1 orign may repeat at stame blocker (M beat-an alpha: 1 orign may repeat at stame blocker (M beat-an alpha: 1 orign may repeat at stame does (M beat-an alpha: 1 0 min before starting drip; adjust drip weey; 15 min; adjust drip boulss; 50 does, 300 mg) IO-30 mg (N every 10 min) adjust drip boulss; 10 min before starting drip; adjust drip by 0 does, 300 mg) Rapid onset (2-10 min) and offset (10-30 min) maximum cumulative does, 300 mg) Selective beta-1 blocker 50-1.000 /gr(jw glous, 16) does, 300 mg) Rapid onset (2-10 min) and offset (10-30 min) bound by 100-300 ug/kg/min V drip; adjust drip by V drip; adjust drip drip V drip; adjust drip by V drip; adjust drip by V drip; adjust drip by V drip; adjust drip drip V drip; adjust drip V drip; adjust drip drip V drip; adjust drip	Clevidipine	Dihydropyridine calcium- channel blocker, vaso- dilator	1–16 mg/hr IV drip; double dose every 90 sec, more slowly as BP approaches goal	Rapid onset (2–4 min) and offset (5–15 min) of action	Contraindicated in patients with acute coronary ischemia (because of reflex tachycardia) and in patients with allergy to soy or eggs; may increase triglyceride levels (it is a lipid emulsion)
Selective beta-1 blocker 500-1,000 μg/kg bolus, fol- lowed by 100-300 μg/kg/min Rapid onset (2–10 min) and offset (10–30 min) of action N drip; adjust drip by SU drip; adjust drip by SU drip; adjust drip by SU drip; adjust drip by SU drip; adjust by 5 min (maxi- mum teld dose, 15 mg) Rapid onset (2–10 min) and offset (10–30 min) Selective beta-1 blocker 2.5-5 mg V vevy 5 min (maxi- mum teld dose, 15 mg) Onset, 15 min; peak, 30–60 min; duration of ac- mum teld dose, 15 mg) Nitrate donor, mixed venous with predominant 10–400 µg/min IV drip; adjust Rapid onset and offset (5–10 min) of action; with prolonged use, a higher dose may be needed for same effect Direct vasolilator with freedominant arteriolar 0.25-10 µg/kg/min IV drip; by 10–20 µg/min Rapid onset and offset (1–2 min) of action; for same effect Direct arterial vasodilator with freedominant arteriolar 0.25-10 µg/kg/min IV drip; adjust by 0.5 µg/kg/min Rapid onset and offset (1–2 min) of action for same effect Direct arterial vasodilator 0.25-10 µg/kg/min Notest and duration of action, 3–6 hr, on accel/ator status; usual onset within 20 min mum dose, 20 mg per free domon fraction free effect Direct arterial vasodilator 5-20 mg IV every 15-20 min, dose) Onset and duration of action, 3–6 hr, on accel/ator status; usual onset within 20 min mum dose, 20 mg per five chronotropic agent to control reflax, tick chronotropic agent to control reflax	Labetalol	Combined nonselective beta-blocker and alpha-1 blocker (IV beta-to-alpha blocking ratio, approx. 7:1)	10-	Rapid onset (5 min) but prolonged duration of action (3–6 hr, sometimes longer at higher doses)	Contraindicated in patients with heart failure, bradycardia or heart block, asthma or severe airway reactivity; caution in cocaine overdose
Selective beta-1 blocker 2:5-5 mg IV every 5 min (maxi- mum total dose, 15 mg), then every 4-6 hr Onset, 15 min; peak, 30-60 min; duration of ac- tion, 4-6 hr; not a very potent antihypertensive then every 4-6 hr Nitrate donor, mixed venous and arteriolar dilator with predominant venous effects 10-40 µg/min U drip; adjust by 10-20 µg/hg/min every 5-15 min Rapid onset and offset (5-10 min) of action; with prolonged use, a higher dose may be needed for same effect Direct vasodilator with reflects 0.25-10 µg/kg/min IV drip; adjust by 0.5 µg/kg/min Rapid onset and offset (1-2 min) of action for same effect Direct arterial vasodilator with reflects 0.25-10 µg/kg/min IV drip; adjust by 0.5 µg/kg/min Rapid onset and offset (1-2 min) of action for same effect Direct arterial vasodilator 5-20 mg IV every 15-20 min, then every 3-4 hr (maxi- mum dose, 20 mg per dose) Onset and duration of action variable, depending on acetylator status; usual onset within 20 min then every 3-4 hr (maxi- mum dose, 20 mg per dose)	Esmolol	Selective beta-1 blocker	8	Rapid onset (2–10 min) and offset (10–30 min) of action	Contraindicated in patients with heart failure, bradycardia or heart block, asthma, cocaine overdose
Nitrate donor, mixed venous and arteriolar dilator with predominant with predominant venous effects 10–400 µg/min IV drip; adjust prolonged use, a higher dose may be needed for some effect 5–15 min Rapid onset and offset (5–10 min) of action; with predominant venous effects Direct vasodilator with predominant arteriolar glust by 0.5 µg/kg/min IV drip; 0.25–10 µg/kg/min IV drip; Rapid onset and offset (1–2 min) of action; with predominant arteriolar adjust by 0.5 µg/kg/min Direct vasodilator with effects 0.25–10 µg/kg/min IV drip; Rapid onset and offset (1–2 min) of action Direct vasodilator with effects 0.25–10 µg/kg/min Notest and offset (1–2 min) of action Direct vasodilator with effects 0.25–10 µg/kg/min Notest and offset (1–2 min) of action Direct vasodilator with effects 0.25–10 µg/kg/min Notest and offset (1–2 min) of action Direct arterial vasodilator 5–20 mg IV every 15–20 min, every 3–4 hr (maxi- mud duration of action variable, depending on active advision Direct arterial vasodilator 5–20 mg IV every 3–4 hr (maxi- mud duration of action variable, depending on active advision Direct arterial vasodilator 5–20 mg IV every 3–4 hr (maxi- mud duration of action variable, depending on active advision Direct arterial vasodilator 5–20 mg IV every 3–4 hr (maxi- mud duration of action variable, depending on active advision Second duration and duration of action variable, depending on active advision	Metoprolol	Selective beta-1 blocker		Onset, 15 min; peak, 30–60 min; duration of ac- tion, 4–6 hr; not a very potent antihypertensive	Contraindicated in patients with heart failure, bradycardia or heart block, asthma, cocaine overdose
Direct vasodilator with predominant arteriolar 0.25–10 µg/kg/min IV drip; adjust by 0.5 µg/kg/min Direct vasodilator servery 5 min every 5 min	Nitroglycerin	Nitrate donor, mixed venous and arteriolar dilator with predominant venous effects	10–400 µg/min IV drip; adjust by 10–20 µg/min every 5–15 min	Rapid onset and offset (5–10 min) of action; with prolonged use, a higher dose may be needed for same effect	Contraindicated in patients with right ventricular infarction
Direct arterial vasodilator 5–20 mg IV every 15–20 min, Onset and duration of action variable, depending then every 3–4 hr (maxi- on acetylator status; usual onset within 20 min mum dose, 20 mg per and peak within 1 hr; duration of action, 3–6 hr; dose) tive chronotropic agent to control reflex tachycardia	Nitroprusside	Direct vasodilator with predominant arteriolar effects		Rapid onset and offset (1–2 min) of action	Contraindicated in pregnancy (risk of fetal cyanide toxicity); use with impaired renal function may lead to thiocyanate toxicity, and use in liver disease may lead to cyanide intoxication, which may occur with higher doses or prolonged infusions; may cause methemoglobinemia (dose-dependent), increased intracranial pressure
	Hydralazine	Direct arterial vasodilator	5–20 mg IV every 15–20 min, then every 3–4 hr (maxi- mum dose, 20 mg per dose)	Onset and duration of action variable, depending on acetylator status; usual onset within 20 min and peak within 1 hr; duration of action, 3–6 hr; often demands a beta-blocker or other nega- tive chronotropic agent to control reflex tachycardia	Use should be avoided in most cases; may worsen ischemia (owing to reflex tachycardia and possible coronary steal); unpredictable BP responses, often excessive

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

sion is greatest in the first 6 hours of intravenous therapy, a reasonable approach is to start oral agents 6 to 12 hours after starting intravenous therapy.⁴⁴ Long-acting drugs are chosen on the basis of standard guidelines for chronic hypertension management.^{1,2} After initial stabilization, experience indicates that most patients can tolerate normalization of blood pressure within 48 to 72 hours, although some require longer periods owing to dizziness, fatigue, or mental slowness.

The recommended pace and intensity of bloodpressure reduction vary depending on the presence of certain conditions, particularly aortic dissection, eclampsia, pheochromocytoma crisis, and intracerebral hemorrhage, all of which demand more aggressive approaches to limit ongoing injury.^{1,3,46} Ischemic stroke^{1,3,47} requires more conservative management to avoid peri-infarction hypoperfusion and worse stroke outcomes. Consensus recommendations are based on very limited data and in some cases are not uniform across guidelines.^{1,3,48,49}

HYPERTENSIVE URGENCIES

Most patients without acute target-organ damage can be cared for as outpatients.¹³⁻¹⁶ Treatment with guideline-concordant long-acting medications^{1,2} should be started, reinstated, or adjusted, and follow-up should be scheduled within 1 to 7 days.

In a study involving more than 500 patients presenting to an emergency department with severe hypertension, blood pressure fell to less than 180/110 mm Hg after 30 minutes of quiet rest (before medication administration) in approximately one third of the patients.¹³ If quiet rest or control of anxiety or other precipitating factors is insufficient, an oral antihypertensive agent may be given. Intravenous medications are discouraged in this context.

For patients with symptoms that are presumed to relate to hypertension but are not indicative of target-organ damage (e.g., headache, atypical chest pain, or epistaxis), it is reasonable to choose an oral agent with a faster onset of action, such as clonidine (0.1 to 0.3 mg), labetalol (200 to 400 mg), captopril (25 to 50 mg), prazosin (5 to 10 mg), or nitroglycerin 2% topical ointment (1 to 2 in.). Nifedipine (given orally or sublingually) should be avoided owing to unpredictable blood-pressure reduction, possibly resulting in cardiovascular events.⁵⁰ Medications can be administered every 30 minutes until the target blood pressure is achieved. A systematic review of comparative trials and cohort studies suggested similar acute blood-pressure reductions with different agents.⁵¹ Clinical experience and descriptions of the acute effects of clonidine and labetalol suggest that they may be associated with less abrupt blood-pressure changes than other agents.⁵²⁻⁵⁴ Patients are generally discharged once symptoms have improved, which often coincides with a decrease in blood pressure to a level below 160 to 180/100 to 110 mm Hg.

AREAS OF UNCERTAINTY

Large randomized trials are lacking to identify the most effective treatment for hypertensive urgencies and emergencies generally and for specific underlying conditions. For previously untreated patients who present to the emergency department, there is controversy regarding whether antihypertensive medication should be prescribed at discharge.⁵⁵ The American College of Emergency Physicians currently recommends initiation of therapy in the emergency department only for selected patients who are likely to have poor follow-up and recommends referral without initiation of treatment in the rest. Although there is reasonable concern about inappropriate treatment of normotensive patients, withholding treatment may represent a missed opportunity to minimize risk.

GUIDELINES

Recommendations for the management of acute severe hypertension are included in major U.S. and European hypertension guidelines.¹⁻³ There are variations in terminology and specific bloodpressure thresholds, but all the guidelines acknowledge the critical role of acute target-organ damage and adopt blood-pressure thresholds of 180/110 to 120 mm Hg to define urgencies and emergencies (Table S3). There is general agreement on the pace of blood-pressure reduction and the need for the use of intravenous drugs in an intensive care environment for the management of hypertensive emergencies. The approach proposed in this article is generally consistent with these guidelines.

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

CONCLUSIONS AND RECOMMENDATIONS

The patient described in the vignette has acute severe hypertension complicated by posterior reversible encephalopathy syndrome, a hypertensive emergency precipitated by nonadherence to antihypertensive therapy. She should be admitted to the intensive care unit and immediately begin treatment with continuous intravenous antihypertensive therapy guided by invasive intraarterial blood-pressure monitoring. Nicardipine (or clevidipine) and labetalol are the preferred agents in this context. Given her relative bradycardia, nicardipine would be my choice. Although data are lacking to guide the appropriate pace of bloodpressure reduction, I would lower her blood pressure by approximately 20 to 25% in the first hour and would aim for a blood pressure of approximately 160/100 mm Hg by 6 hours. If she has a good response and relative hypotension does not develop, I would restart amlodipine and lisinopril at that point. Because stepped additions may reduce the risk of excessive blood-pressure reduction, I would restart her diuretic the following day if needed. I would wean the nicardipine over a period of 18 to 36 hours, although the timing should be guided by close blood-pressure monitoring. I would discharge her once her symptoms improve and hypertension is controlled for at least 24 hours without the use of intravenous therapy, with arrangements for a follow-up office appointment within 1 week. I would not pursue an evaluation for secondary hypertension unless her blood pressure remained uncontrolled at follow-up.

Dr. Peixoto reports receiving grant support, paid to Yale University, from Vascular Dynamics, Bayer, Lundbeck, Otsuka, Allena Pharmaceuticals, and Boehringer Ingelheim, fees for serving on a data and safety monitoring board from Ablative Solutions, and advisory board fees from Relypsa and DiaMedica Therapeutics. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

REFERENCES

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6): e13-e115.

2. Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2018;36:2284-309.

 van den Born BH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on Hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother 2019;5:37-46.
 Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One 2014; 9(4):e93542.

5. Janke AT, McNaughton CD, Brody AM, Welch RD, Levy PD. Trends in the incidence of hypertensive emergencies in US emergency departments from 2006 to 2013. J Am Heart Assoc 2016;5(12):e004511.

6. Aronson S. Perioperative hypertensive emergencies. Curr Hypertens Rep 2014; 16:448.

7. Deshmukh A, Kumar G, Kumar N,

et al. Effect of Joint National Committee VII report on hospitalizations for hypertensive emergencies in the United States. Am J Cardiol 2011;108:1277-82.

8. Shah M, Patil S, Patel B, et al. Trends in hospitalization for hypertensive emergency, and relationship of end-organ damage with in-hospital mortality. Am J Hypertens 2017;30:700-6.

9. Polgreen LA, Suneja M, Tang F, Carter BL, Polgreen PM. Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. Hypertension 2015;65:1002-7.

10. Katz JN, Gore JM, Amin A, et al. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry. Am Heart J 2009;158(4):599-606.e1.

11. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-tovisit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.

12. Vlcek M, Bur A, Woisetschläger C, Herkner H, Laggner AN, Hirschl MM. Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension. J Hypertens 2008;26:657-62.

13. Grassi D, O'Flaherty M, Pellizzari M, et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich) 2008;10:662-7.

14. Levy PD, Mahn JJ, Miller J, et al. Blood pressure treatment and outcomes in hypertensive patients without acute target organ damage: a retrospective cohort. Am J Emerg Med 2015;33:1219-24.

15. Patel KK, Young L, Howell EH, et al. Characteristics and outcomes of patients presenting with hypertensive urgency in the office setting. JAMA Intern Med 2016; 176:981-8.

16. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202: 1028-34.

17. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension 2019; 73(5):e35-e66.

18. Lehman LW, Saeed M, Talmor D, Mark R, Malhotra A. Methods of blood pressure measurement in the ICU. Crit Care Med 2013;41:34-40.

19. Wax DB, Lin HM, Leibowitz AB. Invasive and concomitant noninvasive intraoperative blood pressure monitoring: observed differences in measurements and associated therapeutic interventions. Anesthesiology 2011;115:973-8.

20. Ribezzo S, Spina E, Di Bartolomeo S, Sanson G. Noninvasive techniques for blood pressure measurement are not a reliable alternative to direct measurement: a randomized crossover trial in ICU. Sci World J 2014;2014:353628.

21. Kallioinen N, Hill A, Horswill MS,

N ENGL J MED 381;19 NEJM.ORG NOVEMBER 7, 2019

1851

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.

Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review. J Hypertens 2017;35:421-41.

22. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996; 27:144-7.

23. Saguner AM, Dür S, Perrig M, et al. Risk factors promoting hypertensive crises: evidence from a longitudinal study. Am J Hypertens 2010;23:775-80.

24. Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep 2015; 17:94.

25. Victor RG, Lynch K, Li N, et al. A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med 2018;378:1291-301.

26. Wu JR, Cummings DM, Li Q, et al. The effect of a practice-based multicomponent intervention that includes health coaching on medication adherence and blood pressure control in rural primary care. J Clin Hypertens (Greenwich) 2018; 20:757-64.

27. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3(2):e000718.

28. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018;72(5):e53-e90.
29. Nishijima DK, Paladino L, Sinert R. Routine testing in patients with asymptomatic elevated blood pressure in the ED. Am J Emerg Med 2010;28:235-42.

30. Levy P, Ye H, Compton S, et al. Subclinical hypertensive heart disease in black patients with elevated blood pressure in an inner-city emergency department. Ann Emerg Med 2012;60(4):467-74.e1.

31. Martin JF, Higashiama E, Garcia E, Luizon MR, Cipullo JP. Hypertensive crisis profile: prevalence and clinical presentation. Arq Bras Cardiol 2004;83:131-6.

32. Karras DJ, Kruus LK, Cienki JJ, et al. Evaluation and treatment of patients with severely elevated blood pressure in academic emergency departments: a multicenter study. Ann Emerg Med 2006;47: 230-6.

33. Reed G, Devous M. Cerebral blood flow autoregulation and hypertension. Am J Med Sci 1985;289:37-44.

34. Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients: the modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 1976;53:720-7.

35. Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973;1:507-10.

36. Zhang R, Witkowski S, Fu Q, Claassen JA, Levine BD. Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension. Hypertension 2007;49:1149-55.

37. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 2008;22:596-607.

38. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008;107:1110-21.
39. Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 2011;15:R157.

40. Vuylsteke A, Vincent JL, de La Garanderie DP, et al. Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT). Crit Care 2011;15:R271.

41. Campbell P, Baker WL, Bendel SD, White WB. Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified. J Am Soc Hypertens 2011;5:473-7.

42. Liu-DeRyke X, Levy PD, Parker D Jr, Coplin W, Rhoney DH. A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. Neurocrit Care 2013; 19:41-7.

43. Peacock WF IV, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med 2012;30:981-93.

44. Mayer SA, Kurtz P, Wyman A, et al. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension registry. Crit Care Med 2011;39:2330-6.

45. Peacock F, Amin A, Granger CB, et al. Hypertensive heart failure: patient characteristics, treatment, and outcomes. Am J Emerg Med 2011;29:855-62. **46.** Hemphill JC III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015;46:2032-60.

47. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49(3):e46-e110.

48. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.

49. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 2015;65:1372-407.

50. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996;276:1328-31.

51. Campos CL, Herring CT, Ali AN, et al. Pharmacologic treatment of hypertensive urgency in the outpatient setting: a systematic review. J Gen Intern Med 2018;33: 539-50.

52. Atkin SH, Jaker MA, Beaty P, Quadrel MA, Cuffie C, Soto-Greene ML. Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. Am J Med Sci 1992;303:9-15.

53. Greene CS, Gretler DD, Cervenka K, McCoy CE, Brown FD, Murphy MB. Cerebral blood flow during the acute therapy of severe hypertension with oral clonidine. Am J Emerg Med 1990;8:293-6.

54. Jaker M, Atkin S, Soto M, Schmid G, Brosch F. Oral nifedipine vs oral clonidine in the treatment of urgent hypertension. Arch Intern Med 1989;149:260-5.

55. Wolf SJ, Lo B, Shih RD, Smith MD, Fesmire FM. Clinical policy: critical issues in the evaluation and management of adult patients in the emergency department with asymptomatic elevated blood pressure. Ann Emerg Med 2013;62:59-68.

Copyright © 2019 Massachusetts Medical Society.

N ENGLJ MED 381;19 NEJM.ORG NOVEMBER 7, 2019

The New England Journal of Medicine

Downloaded from nejm.org by EDWARD STEHLIK on November 17, 2019. For personal use only. No other uses without permission.